Yuhan Corporation – Introduction Video

Yuhan USA
September 22, 2021

Share This Post

Learn more about our parent company “Yuhan Corporation by watching this video.

More To Explore

Yuhan Presents Preclinical Data on Targeted Therapy YH42946 and Bispecific Immunotherapy YH32364

At the AACR 2025 Annual Meeting, Yuhan Corporation unveiled promising preclinical results for two of its cancer drug candidates: YH42946, a HER2/EGFR tyrosine kinase inhibitor

Yuhan May 9, 2025

Yuhan’s HER2×4-1BB Bispecific Antibody YH32367 Shows Early Efficacy and Safety in Phase 1 Solid Tumor Trial

At the AACR 2025 Annual Meeting, Yuhan Corporation presented encouraging interim results from a Phase 1 trial of YH32367, a bispecific antibody targeting HER2 and

Yuhan May 9, 2025